Navigating 6 Analyst Ratings For Viridian Therapeutics
Portfolio Pulse from Benzinga Insights
Viridian Therapeutics (NASDAQ:VRDN) has received mixed analyst ratings over the past three months, with a recent shift towards more bullish perspectives. The average 12-month price target for VRDN has been adjusted to $35.83, down from $37.00, reflecting a 3.16% decrease. The company, a clinical-stage biopharmaceutical firm focusing on thyroid eye disease treatments, faces financial challenges, including a significant revenue decline and below-industry benchmarks in profitability and asset utilization.
February 28, 2024 | 2:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Viridian Therapeutics has seen a recent shift towards more bullish analyst ratings, with a revised average 12-month price target of $35.83. Financial challenges persist, marked by a significant revenue decline and below-industry performance metrics.
The mixed analyst ratings with a slight shift towards bullish perspectives indicate uncertainty about VRDN's short-term stock price movement. The financial challenges and below-industry performance metrics could dampen investor enthusiasm, balancing the potential positive impact of the bullish ratings. The revised average price target suggests a cautious optimism from analysts, reflecting both the company's innovative focus and its current financial hurdles.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100